Conference Correspondent

Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM

Conference Correspondent 

Ishida and colleagues reported interim results of a phase 2 trial that evaluated reduced- intensity bortezomib/melphalan/prednisolone (VMP) followed by lenalidomide/low-dose dexamethasone (Rd) consolidation therapy and lenalidomide maintenance therapy to improve outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). In this Japanese trial, 82 patients with newly diagnosed MM received 5 cycles of VMP (bortezomib 1.3 mg/m2 intravenously or subcutaneously weekly; oral melphalan 6 mg/m2; and prednisone 60 mg/m2 once daily on days 1-4 of a 35-day cycle), followed by 6 cycles of Rd (lenalidomide 25 mg daily on days 1-21; dexamethasone 40 mg weekly of a 28-day cycle), and lenalidomide maintenance therapy (10 mg daily on days 1-21 of a 28-day cycle).1  

Median age of the study population was 73.5 years; 16.3% of 80 evaluated patients had t(4;14), 10% had del 17p, and 41.3% had +1q21 cytogenetic abnormalities. After 5 cycles of VMP induction therapy, the best response of ≥partial response (PR) was 68%, including complete response (CR) in 6% of patients, stringent CR (sCR) in 5%, very good partial response (VGPR) in 20%, and PR in 37% of patients. The best response rate (≥PR) after VMP induction and 6 cycles of Rd consolidation therapy was 90%, including sCR in 6%, CR in 16%, VGPR in 39%, and PR in 29% of patients. In the subgroup of patients with unfavorable cytogenetic characteristics (del 17p or t[4;14]), 58% achieved ≥VGPR and 90% achieved ≥PR. Most common grade ≥3 adverse events experienced by patients during VMP induction therapy were anemia (30%), neutropenia (16%), thrombocytopenia (5%), and gastrointestinal toxicity (6%). Overall, the authors concluded that reduced-intensity (5 cycles) VMP was safe and effective in transplant-ineligible patients with newly diagnosed MM, including those with high-risk cytogenetics.

  1. Ishida T, et al. ASH 2015. Abstract 3043.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: